Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FinNiss trial: Probiotic E. coli Nissle for prevention of urinary tract infections in infants and young children
2020-001769-35Phase 4
- Sponsor
- Oulu University Hospital
- Start
- May 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of escherichia coli nissle 1917 in urinary tract infection (UTI), sponsored by Oulu University Hospital. Primary endpoint: Proportion of children with new urinary tract infection during follow-up.
02
Drugs
escherichia coli nissle 1917
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2020-001769-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001769-35.